NO20051900L - Kinazolinderivater som SRC tyrosin kinase inhibitorer - Google Patents
Kinazolinderivater som SRC tyrosin kinase inhibitorerInfo
- Publication number
- NO20051900L NO20051900L NO20051900A NO20051900A NO20051900L NO 20051900 L NO20051900 L NO 20051900L NO 20051900 A NO20051900 A NO 20051900A NO 20051900 A NO20051900 A NO 20051900A NO 20051900 L NO20051900 L NO 20051900L
- Authority
- NO
- Norway
- Prior art keywords
- group
- quinazoline derivatives
- tyrosine kinase
- kinase inhibitors
- src tyrosine
- Prior art date
Links
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title abstract 2
- 102000009076 src-Family Kinases Human genes 0.000 title 1
- 108010087686 src-Family Kinases Proteins 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000001740 anti-invasion Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Oppfinnelsen angår kinazolinderivater med formel I, hvor Z er O-, S-, SO-, S02-, N(R2)- eller C(R2)2-gruppe hvor hver R2-gruppe er hydrogen eller (1-8C)alkyl, m er 0, 1, 2 eller 3, hver R1-gruppe er valgt fra halogen, (1-8C)alkyl, (1-6C)alkoksy og hvilken som helst av de andre betydninger definert i be skrivelsen, n er 0, 1, 2 eller 3 og hver R 3-gruppe er valgt fra halogen, (1-8C)alkyl, (1-6C)alkoksy og hvilken som helst av de andre betydninger definert i beskrivelsen, eller farmasøytisk akseptable salter derav, fremgangsmåter for deres fremstilling, farmasøytiske preparater inneholdende dem og anvendelse av dem ved fremstilling av et medikament for anvendelse som et anti-invasivt middel ved begrensning og/eller behandling av fast tumor-sykdom.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02292736 | 2002-11-04 | ||
| EP03290900 | 2003-04-10 | ||
| PCT/GB2003/004703 WO2004041829A1 (en) | 2002-11-04 | 2003-10-29 | Quinazoline derivatives as src tyrosine kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20051900L true NO20051900L (no) | 2005-06-01 |
| NO331951B1 NO331951B1 (no) | 2012-05-14 |
Family
ID=32313852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20051900A NO331951B1 (no) | 2002-11-04 | 2005-04-19 | Kinazolinderivater, farmasoytisk preparat inneholdende slike samt anvendelse av slike for fremstilling av medikament for behandling av sykdom |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7462623B2 (no) |
| EP (1) | EP1562955B1 (no) |
| JP (2) | JP4593464B2 (no) |
| KR (1) | KR101089462B1 (no) |
| AR (1) | AR041884A1 (no) |
| AT (1) | ATE387451T1 (no) |
| AU (1) | AU2003278383B2 (no) |
| BR (1) | BR0315756A (no) |
| CA (1) | CA2503371C (no) |
| CO (1) | CO5560578A2 (no) |
| CY (1) | CY1108061T1 (no) |
| DE (1) | DE60319410T2 (no) |
| DK (1) | DK1562955T3 (no) |
| EG (1) | EG24957A (no) |
| ES (1) | ES2300619T3 (no) |
| IL (1) | IL168013A (no) |
| IS (1) | IS2568B (no) |
| MX (1) | MXPA05004858A (no) |
| MY (1) | MY137835A (no) |
| NO (1) | NO331951B1 (no) |
| NZ (1) | NZ539408A (no) |
| PL (1) | PL215161B1 (no) |
| PT (1) | PT1562955E (no) |
| RU (1) | RU2350618C2 (no) |
| SI (1) | SI1562955T1 (no) |
| TW (1) | TWI320786B (no) |
| WO (1) | WO2004041829A1 (no) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2280003B1 (en) | 2002-07-15 | 2014-04-02 | Symphony Evolution, Inc. | Process for preparing receptor-type kinase modulators |
| EP2392565B1 (en) | 2003-09-26 | 2014-03-19 | Exelixis, Inc. | c-Met modulators and methods of use |
| GB0406445D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
| GB0427697D0 (en) * | 2004-12-17 | 2005-01-19 | Astrazeneca Ab | Chemical process |
| ZA200706804B (en) * | 2005-02-03 | 2008-10-29 | Gen Hospital Corp | Method for treating gefitinib resistant cancer |
| WO2009068906A2 (en) * | 2007-11-26 | 2009-06-04 | Astrazeneca Ab | Combinations comprising zd4054 and a src family kinase inhibitor 172 |
| RS52754B2 (sr) | 2009-01-16 | 2022-08-31 | Exelixis Inc | Malat so n-(4- {[6,7-bis(metiloksi)hinolin-4-il]oksi}fenil-n'- (4-fluorofenil) ciklopropan-1,1-dikarboksamid-a, i njeni kristalni oblici za lečenje karcinoma |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| PL2621481T5 (pl) | 2010-09-27 | 2023-03-13 | Exelixis, Inc. | Podwójne inhibitory MET i VEGF do leczenia opornego na kastrację raka prostaty i osteoblastycznych przerzutów do kości |
| TWI577671B (zh) | 2011-11-14 | 2017-04-11 | Sunshine Lake Pharma Co Ltd | Aminoquinazoline derivatives and salts thereof and methods of use thereof |
| WO2017062500A2 (en) | 2015-10-05 | 2017-04-13 | The Trustees Of Columbia University In The City Of New York | Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| PT3849534T (pt) | 2018-09-10 | 2025-04-01 | Mirati Therapeutics Inc | Combinação de dasatinib e adagrasib para utilização no tratamento de cancro do pulmão de células não pequenas |
| CN119504612A (zh) * | 2024-11-18 | 2025-02-25 | 中国海洋大学 | 一种喹唑啉茋类衍生物及其制备方法和应用 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| AU658646B2 (en) | 1991-05-10 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
| AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9205320D0 (en) * | 1992-03-11 | 1992-04-22 | Ici Plc | Anti-tumour compounds |
| GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US6046206A (en) | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
| GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| JP4471404B2 (ja) | 1996-02-13 | 2010-06-02 | アストラゼネカ ユーケイ リミテッド | Ｖｅｇｆインヒビターとしてのキナゾリン誘導体 |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| ATE211134T1 (de) | 1996-03-05 | 2002-01-15 | 4-anilinochinazolin derivate | |
| WO1997034876A1 (en) | 1996-03-15 | 1997-09-25 | Zeneca Limited | Cinnoline derivatives and use as medicine |
| GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
| JP4386967B2 (ja) | 1996-07-13 | 2009-12-16 | グラクソ、グループ、リミテッド | プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物 |
| WO1998013350A1 (en) | 1996-09-25 | 1998-04-02 | Zeneca Limited | Qinoline derivatives inhibiting the effect of growth factors such as vegf |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| ATE368665T1 (de) | 1997-08-22 | 2007-08-15 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
| PL201475B1 (pl) | 1998-09-29 | 2009-04-30 | Wyeth Corp | Podstawione 3-cyjanochinoliny jako inhibitory białkowych kinaz tyrozynowych |
| DK1119567T3 (da) | 1998-10-08 | 2005-07-25 | Astrazeneca Ab | Quinazolinderivater |
| DK1553097T3 (da) | 1999-02-10 | 2010-12-13 | Astrazeneca Ab | Quinazolinderivat som angiogeneseinhibitor og mellemprodukter dertil |
| GB9922171D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| CZ20021010A3 (cs) | 1999-09-21 | 2002-06-12 | Astrazeneca Ab | Nové sloučeniny chinazolinu a farmaceutické kompozice, které je obsahují |
| PL203782B1 (pl) | 1999-11-05 | 2009-11-30 | Astrazeneca Ab | Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania |
| JP2003525897A (ja) | 2000-03-06 | 2003-09-02 | アストラゼネカ アクチボラグ | 治 療 |
| GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| AU779695B2 (en) | 2000-04-07 | 2005-02-10 | Astrazeneca Ab | Quinazoline compounds |
| UA73993C2 (uk) * | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| JP2004505964A (ja) | 2000-08-09 | 2004-02-26 | アストラゼネカ アクチボラグ | Ｖｅｇｆ阻害活性を有するキノリン誘導体 |
| WO2002012227A2 (en) | 2000-08-09 | 2002-02-14 | Astrazeneca Ab | Indole, azaindole and indazole derivatives having vegf inhibiting activity |
| WO2002012228A1 (en) | 2000-08-09 | 2002-02-14 | Astrazeneca Ab | Cinnoline compounds |
| AU2001278609B2 (en) | 2000-08-21 | 2005-04-14 | Astrazeneca Ab | Quinazoline derivatives |
| WO2002030926A1 (en) | 2000-10-13 | 2002-04-18 | Astrazeneca Ab | Quinazoline derivatives |
| AU2001292138A1 (en) | 2000-10-13 | 2002-04-22 | Astrazeneca Ab | Quinazoline derivatives with anti-tumour activity |
| JP2004512335A (ja) | 2000-10-25 | 2004-04-22 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
| EP1381599B1 (en) | 2001-04-19 | 2008-09-24 | Astrazeneca AB | Quinazoline derivatives |
| WO2002092578A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
| WO2002092579A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
| WO2002092577A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
| ATE341545T1 (de) | 2001-07-16 | 2006-10-15 | Astrazeneca Ab | Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase |
| GB0126879D0 (en) | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| WO2003047582A1 (en) | 2001-12-05 | 2003-06-12 | Astrazeneca Ab | Quinoline derivatives as antitumour agents |
| DK1474420T3 (da) | 2002-02-01 | 2012-05-21 | Astrazeneca Ab | Quinazolinforbindelser |
| GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
| US7504408B2 (en) | 2002-07-09 | 2009-03-17 | Astrazeneca Ab | Quinzoline derivatives for use in the treatment of cancer |
| WO2004014383A1 (en) | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
| GB0218526D0 (en) | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| GB0223380D0 (en) | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| GB0226434D0 (en) * | 2002-11-13 | 2002-12-18 | Astrazeneca Ab | Combination product |
| ATE506062T1 (de) | 2003-02-13 | 2011-05-15 | Astrazeneca Ab | Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11 |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
-
2003
- 2003-10-29 NZ NZ539408A patent/NZ539408A/en not_active IP Right Cessation
- 2003-10-29 US US10/533,931 patent/US7462623B2/en not_active Expired - Fee Related
- 2003-10-29 WO PCT/GB2003/004703 patent/WO2004041829A1/en not_active Ceased
- 2003-10-29 AU AU2003278383A patent/AU2003278383B2/en not_active Ceased
- 2003-10-29 BR BR0315756-3A patent/BR0315756A/pt not_active IP Right Cessation
- 2003-10-29 CA CA2503371A patent/CA2503371C/en not_active Expired - Fee Related
- 2003-10-29 RU RU2005117337/04A patent/RU2350618C2/ru not_active IP Right Cessation
- 2003-10-29 ES ES03769689T patent/ES2300619T3/es not_active Expired - Lifetime
- 2003-10-29 MX MXPA05004858A patent/MXPA05004858A/es active IP Right Grant
- 2003-10-29 AT AT03769689T patent/ATE387451T1/de active
- 2003-10-29 DE DE60319410T patent/DE60319410T2/de not_active Expired - Lifetime
- 2003-10-29 SI SI200331192T patent/SI1562955T1/sl unknown
- 2003-10-29 DK DK03769689T patent/DK1562955T3/da active
- 2003-10-29 JP JP2005502127A patent/JP4593464B2/ja not_active Expired - Fee Related
- 2003-10-29 KR KR1020057007855A patent/KR101089462B1/ko not_active Expired - Fee Related
- 2003-10-29 PT PT03769689T patent/PT1562955E/pt unknown
- 2003-10-29 EP EP03769689A patent/EP1562955B1/en not_active Expired - Lifetime
- 2003-10-29 PL PL376255A patent/PL215161B1/pl unknown
- 2003-10-30 TW TW092130284A patent/TWI320786B/zh not_active IP Right Cessation
- 2003-11-03 MY MYPI20034197A patent/MY137835A/en unknown
- 2003-11-04 AR ARP030104036A patent/AR041884A1/es not_active Application Discontinuation
-
2005
- 2005-04-13 IL IL168013A patent/IL168013A/en not_active IP Right Cessation
- 2005-04-19 NO NO20051900A patent/NO331951B1/no not_active IP Right Cessation
- 2005-04-30 EG EGNA2005000178 patent/EG24957A/xx active
- 2005-05-03 CO CO05042313A patent/CO5560578A2/es not_active Application Discontinuation
- 2005-05-19 IS IS7849A patent/IS2568B/is unknown
-
2008
- 2008-04-24 CY CY20081100460T patent/CY1108061T1/el unknown
-
2010
- 2010-07-26 JP JP2010167576A patent/JP2010270143A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20082643L (no) | Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft | |
| NO20061743L (no) | Kinazolinderivater | |
| NO20084872L (no) | 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig | |
| NO20084845L (no) | 2-pyrazinonderivater for behandling av sykdom eller tilstander der inhibiering av neutrofil elastaseaktivitetet er gunstig | |
| DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
| NO20071703L (no) | Kinazolinderivater | |
| NO20072259L (no) | Heteroaryltiazoler og deres anvendelse som P13K-inhibitorer | |
| NO20051010L (no) | Triazolderivater som transformerende vekst faktor (TGF) inhibitorer | |
| NO20090631L (no) | Morpholin pyrimidin derivativer anvendelige i behandlingen av proliferative lidelser | |
| NO20051900L (no) | Kinazolinderivater som SRC tyrosin kinase inhibitorer | |
| NO20061746L (no) | Kinazolinderivater som antiproliferative midler | |
| NO20092033L (no) | Nye forbindelser | |
| BR0310106A (pt) | Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica | |
| NO20060415L (no) | Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer | |
| NO20063382L (no) | Nye kinolinderivater | |
| NO20090443L (no) | 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater | |
| NO20061657L (no) | Pyrolderivater med antibakteriell aktivitet | |
| DE60215178D1 (de) | Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase | |
| NO20055496L (no) | Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer | |
| HUP0202490A2 (hu) | Indazolszármazékok és ezeket tartalmazó protein-kináz gátló hatású gyógyszerkészítmények | |
| NO20090328L (no) | Nye forbindelser 385 | |
| HUP0401638A2 (hu) | Daganatellenes hatású tiofén- és tiazolszulfonamid származékok, valamint ezeket tartalmazó gyógyászati készítmények | |
| NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
| NO20081844L (no) | Terapeutiske forbindelser | |
| BR0312464A (pt) | Inibidores de tirosina quinases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |